1.5 Ni wt %/Al2O3 catalysts have been prepared by incipient wetness impregnation using [Ni(diamine)x(H2O)(6-2x)]Y2 precursors (diamine = 1,2-ethanediamine (en) and trans-1,2-cyclohexanediamine (tc); x = 0, 1, and 2; Y = NO3- and Cl-), to avoid the formation, during calcination, of difficult-to-reduce nickel aluminate. N2 was chosen for thermal treatment to help reveal and take advantage of the reactions occurring between Ni2+, ligands, counterions, and support. In the case of [Ni(en)2(H2O)2]Y2 salts used as precursors, in situ UV-vis and DRIFT spectroscopies show that after treatment at 230 degrees C Ni(II) ions are grafted to alumina via two OAl bonds and that the diamine ligands still remain coordinated to grafted nickel ions but in a monodentate way, bridging the cation with the alumina surface. With Y = Cl-, the chloride counterions desorb as hydrogen chloride, and hydrogen released upon decomposition of the en ligands is able to reduce a fraction of nickel ions into metal as evidenced by XPS. In contrast, with Y = NO3-, compounds such as CO or NO are formed during thermal treatment, indicating that nitrate ions burn the en ligands. After thermal treatment at 500 degrees C, a surface phase containing Ni(II) ions forms, characterized by XPS and UV-vis spectroscopy. Temperature-programmed reduction shows that these ions can be quantitatively reduced to the metallic state at 500 degrees C, in contrast with the aluminate obtained when the preparation is carried out from [Ni(H2O)6]2+, which is reduced only partly at 950 degrees C. On the other hand, a total self-reduction of nickel complexes leading to 2-5-nm metal particles is obtained upon thermal treatment via the hydrogen released by a hydrogen-rich ligand such as tc, whatever the Y counterion. An appropriate choice of the ligand and the counterion allows then to obtain selectively Ni(II) ions or a dispersed reduced nickel phase after treatment in N2, as a result of the reactions occurring between the chemical partners present on alumina.
A Ni 0 (15 wt %)/Al 2 O 3 catalyst is prepared by impregnation using [Ni(en) 2 (H 2 O) 2 ](NO 3 ) 2 as precursor salt containing the chelating ligand ethylenediamine (en). Due to the low solubility of this salt and the high viscosity of its solution, large crystals of the salt deposit on the support, clogging the porosity of alumina. These crystals split during the thermal treatment in argon; hydrogen produced in situ from organic residues reduces quantitatively nickel (II) to monodisperse small Ni 0 particles, compared with only one half of nickel reduced by hydrogen when catalysts are prepared from [Ni(H 2 O) 6 ](NO 3 ) 2 . To cite this article:
When NiOx/Al2O3 catalysts (Ni wt% = 1.5) are prepared by impregnation using [NiL2(H2O)2]X2 as precursors (L = diamine, X = Cl- or NO3-), a supported oxidic or metallic phase can be selectively obtained after thermal treatment in N2 depending on the nature of the ligand and counter anion; the oxidic phase can be reduced at a lower temperature than the classical nickel aluminate phase obtained from [Ni-(H2O)6](NO3)2.
Ni (7 wt%)/Al2O3 catalysts prepared by decomposition of Ni(II)-ethylenediamine complexes in inert atmosphere initially contain a mixture of metallic and oxidized nickel. X-ray photoelectron spectroscopy shows that after a hydrogen treatment at 500°C, the system contains more metallic nickel than catalysts prepared from the usual precursor, nickel nitrate. Carbonaceous species resulting from the partial oxidation of ethylenediamine are also eliminated. The catalyst post-treated in hydrogen exhibits a high metallic surface area accessible to reactants and is able to catalyze CO methanation
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.